MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Jack H. Simon; P. O'Connor; P. Fleming; T. Gray; L. Jacobs; C. Miller; F. Munschauer; R. P. Kinkel; D. Bolibrush; J. Cohen; M. Freedman; U. Webb; H. Rabinowicz; L. M. Metz; D. Patry; M. Yeung; S. Peters; S. Hashimoto; W. Morrison; J. Oger; H. Panitch; K. Costello; C. Bever; W. Stuart; D. Court; D. Stuart; C. Tornatore; D. Bartlett; J. Richert; P. Duquette; R. Dubois; G. Bernier; T. Scott; L. Pappert; J. Brillman; W. Felton; T. Anderson; J. Astruc; J. Rose; J. Kline; J. Burns; T. Murray; P. Weldon; V. Bhan; C. E. Maxner; M. Wall; L. Vining; T. Grabowski; B. Apatoff; C. Orapello; J. Friedman; S. Galetta; D. Pfohl; G. Liu; G. Rice; T. Bental; P. Mandalfino; E. Eggenberger; D. Snider; D. Kaufman; J. Guarnaccia; R. Lesser; J. Goldstein; M. Reiss; E. Carter; G. Glista; L. Rolak; L. Scheller; D. Jacobson; J. Warner; A. Goodman; M. Petrie; D. Mattson; K. Karlin; A. Wallin; D. Stefoski; S. Brod; E. Cerretta; J. Wolinsky; D. Arnold; R. Arnoutelis; L. Durcan; M. Kupersmith; L. Cappolino; J. Herbert; J. Rosenberg; D. McHugh; A. Blumenfeld; C. Smith; D. Kuder; S. Hamilton; S. Thurston; J. McGee; J. O'Bannon; M. Kaufman; M. Butler; S. Putnam; K. Ramohan; A. Siffort

doi:10.1212/wnl.59.7.998

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Jack H. Simon, P. O'Connor, P. Fleming, T. Gray, L. Jacobs, C. Miller, F. Munschauer, R. P. Kinkel, D. Bolibrush, J. Cohen, M. Freedman, U. Webb, H. Rabinowicz, L. M. Metz, D. Patry, M. Yeung, S. Peters, S. Hashimoto, W. Morrison, J. OgerH. Panitch, K. Costello, C. Bever, W. Stuart, D. Court, D. Stuart, C. Tornatore, D. Bartlett, J. Richert, P. Duquette, R. Dubois, G. Bernier, T. Scott, L. Pappert, J. Brillman, W. Felton, T. Anderson, J. Astruc, J. Rose, J. Kline, J. Burns, T. Murray, P. Weldon, V. Bhan, C. E. Maxner, M. Wall, L. Vining, T. Grabowski, B. Apatoff, C. Orapello, J. Friedman, S. Galetta, D. Pfohl, G. Liu, G. Rice, T. Bental, P. Mandalfino, E. Eggenberger, D. Snider, D. Kaufman, J. Guarnaccia, R. Lesser, J. Goldstein, M. Reiss, E. Carter, G. Glista, L. Rolak, L. Scheller, D. Jacobson, J. Warner, A. Goodman, M. Petrie, D. Mattson, K. Karlin, A. Wallin, D. Stefoski, S. Brod, E. Cerretta, J. Wolinsky, D. Arnold, R. Arnoutelis, L. Durcan, M. Kupersmith, L. Cappolino, J. Herbert, J. Rosenberg, D. McHugh, A. Blumenfeld, C. Smith, D. Kuder, S. Hamilton, S. Thurston, J. McGee, J. O'Bannon, M. Kaufman, M. Butler, S. Putnam, K. Ramohan, A. Siffort

Résultat de recherche: Article › examen par les pairs

90 Citations (Scopus)

Résumé

Objective: To assess the ability of baseline MRI characteristics to predict the early development of clinically definite MS (CDMS) and combined CDMS/MRI outcomes in 190 patients with a positive MRI at the time of their first demyelinating event. Methods: Based on individual and sets of baseline MRI characteristics, the authors evaluated the percentage of patients meeting outcomes of CDMS and various combined CDMS/MRI outcomes by 18 months. They also optimized a cutpoint for dichotomizing each baseline MRI characteristic and evaluated these variables using logistic regression to determine which MRI characteristics best predicted CDMS by 18 months. Results: The presence of two or more gadolinium-enhancing lesions better predicted the development of CDMS and combined CDMS/MRI outcomes by 18 months than any other individual MRI characteristic or set of MRI characteristics. Among patients with two or more gadolinium-enhancing lesions, 52% developed CDMS compared with 24% of patients with fewer than two lesions. For those meeting the criteria of Barkhof et al., 32% of patients developed CDMS compared with 16% of those not meeting these criteria. Irrespective of individual or sets of criteria, however, the majority of patients developed either CDMS or demonstrated disease activity on brain MRI by 18 months. Conclusions: For patients with positive MRI at the time of their initial neurologic event, both gadolinium-enhancing lesions and the Barkhof criteria are predictors for development of CDMS over a short interval. However, these results, based on a combined CDMS/MRI outcome, suggest that the majority of these patients are already in the earliest stages of MS, regardless of whether any further MRI criteria are met.

Langue d'origine	English
Pages (de-à)	998-1005
Nombre de pages	8
Journal	Neurology
Volume	59
Numéro de publication	7
DOI	https://doi.org/10.1212/wnl.59.7.998
Statut de publication	Published - oct. 8 2002
Publié à l'externe	Oui

ASJC Scopus Subject Areas

Clinical Neurology

Accès au document

10.1212/wnl.59.7.998

Autres fichiers et liens

Citer

Simon, J. H., O'Connor, P., Fleming, P., Gray, T., Jacobs, L., Miller, C., Munschauer, F., Kinkel, R. P., Bolibrush, D., Cohen, J., Freedman, M., Webb, U., Rabinowicz, H., Metz, L. M., Patry, D., Yeung, M., Peters, S., Hashimoto, S., Morrison, W., ... Siffort, A. (2002). MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology, 59(7), 998-1005. https://doi.org/10.1212/wnl.59.7.998

Simon, JH, O'Connor, P, Fleming, P, Gray, T, Jacobs, L, Miller, C, Munschauer, F, Kinkel, RP, Bolibrush, D, Cohen, J, Freedman, M, Webb, U, Rabinowicz, H, Metz, LM, Patry, D, Yeung, M, Peters, S, Hashimoto, S, Morrison, W, Oger, J, Panitch, H, Costello, K, Bever, C, Stuart, W, Court, D, Stuart, D, Tornatore, C, Bartlett, D, Richert, J, Duquette, P, Dubois, R, Bernier, G, Scott, T, Pappert, L, Brillman, J, Felton, W, Anderson, T, Astruc, J, Rose, J, Kline, J, Burns, J, Murray, T, Weldon, P, Bhan, V, Maxner, CE, Wall, M, Vining, L, Grabowski, T, Apatoff, B, Orapello, C, Friedman, J, Galetta, S, Pfohl, D, Liu, G, Rice, G, Bental, T, Mandalfino, P, Eggenberger, E, Snider, D, Kaufman, D, Guarnaccia, J, Lesser, R, Goldstein, J, Reiss, M, Carter, E, Glista, G, Rolak, L, Scheller, L, Jacobson, D, Warner, J, Goodman, A, Petrie, M, Mattson, D, Karlin, K, Wallin, A, Stefoski, D, Brod, S, Cerretta, E, Wolinsky, J, Arnold, D, Arnoutelis, R, Durcan, L, Kupersmith, M, Cappolino, L, Herbert, J, Rosenberg, J, McHugh, D, Blumenfeld, A, Smith, C, Kuder, D, Hamilton, S, Thurston, S, McGee, J, O'Bannon, J, Kaufman, M, Butler, M, Putnam, S, Ramohan, K & Siffort, A 2002, 'MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group', Neurology, vol. 59, n° 7, pp. 998-1005. https://doi.org/10.1212/wnl.59.7.998

@article{a8b163c95ce34e8e94ac0e55f0662d20,

title = "MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group",

abstract = "Objective: To assess the ability of baseline MRI characteristics to predict the early development of clinically definite MS (CDMS) and combined CDMS/MRI outcomes in 190 patients with a positive MRI at the time of their first demyelinating event. Methods: Based on individual and sets of baseline MRI characteristics, the authors evaluated the percentage of patients meeting outcomes of CDMS and various combined CDMS/MRI outcomes by 18 months. They also optimized a cutpoint for dichotomizing each baseline MRI characteristic and evaluated these variables using logistic regression to determine which MRI characteristics best predicted CDMS by 18 months. Results: The presence of two or more gadolinium-enhancing lesions better predicted the development of CDMS and combined CDMS/MRI outcomes by 18 months than any other individual MRI characteristic or set of MRI characteristics. Among patients with two or more gadolinium-enhancing lesions, 52% developed CDMS compared with 24% of patients with fewer than two lesions. For those meeting the criteria of Barkhof et al., 32% of patients developed CDMS compared with 16% of those not meeting these criteria. Irrespective of individual or sets of criteria, however, the majority of patients developed either CDMS or demonstrated disease activity on brain MRI by 18 months. Conclusions: For patients with positive MRI at the time of their initial neurologic event, both gadolinium-enhancing lesions and the Barkhof criteria are predictors for development of CDMS over a short interval. However, these results, based on a combined CDMS/MRI outcome, suggest that the majority of these patients are already in the earliest stages of MS, regardless of whether any further MRI criteria are met.",

author = "Simon, {Jack H.} and P. O'Connor and P. Fleming and T. Gray and L. Jacobs and C. Miller and F. Munschauer and Kinkel, {R. P.} and D. Bolibrush and J. Cohen and M. Freedman and U. Webb and H. Rabinowicz and Metz, {L. M.} and D. Patry and M. Yeung and S. Peters and S. Hashimoto and W. Morrison and J. Oger and H. Panitch and K. Costello and C. Bever and W. Stuart and D. Court and D. Stuart and C. Tornatore and D. Bartlett and J. Richert and P. Duquette and R. Dubois and G. Bernier and T. Scott and L. Pappert and J. Brillman and W. Felton and T. Anderson and J. Astruc and J. Rose and J. Kline and J. Burns and T. Murray and P. Weldon and V. Bhan and Maxner, {C. E.} and M. Wall and L. Vining and T. Grabowski and B. Apatoff and C. Orapello and J. Friedman and S. Galetta and D. Pfohl and G. Liu and G. Rice and T. Bental and P. Mandalfino and E. Eggenberger and D. Snider and D. Kaufman and J. Guarnaccia and R. Lesser and J. Goldstein and M. Reiss and E. Carter and G. Glista and L. Rolak and L. Scheller and D. Jacobson and J. Warner and A. Goodman and M. Petrie and D. Mattson and K. Karlin and A. Wallin and D. Stefoski and S. Brod and E. Cerretta and J. Wolinsky and D. Arnold and R. Arnoutelis and L. Durcan and M. Kupersmith and L. Cappolino and J. Herbert and J. Rosenberg and D. McHugh and A. Blumenfeld and C. Smith and D. Kuder and S. Hamilton and S. Thurston and J. McGee and J. O'Bannon and M. Kaufman and M. Butler and S. Putnam and K. Ramohan and A. Siffort",

year = "2002",

month = oct,

day = "8",

doi = "10.1212/wnl.59.7.998",

language = "English",

volume = "59",

pages = "998--1005",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

AU - Simon, Jack H.

AU - O'Connor, P.

AU - Fleming, P.

AU - Gray, T.

AU - Jacobs, L.

AU - Miller, C.

AU - Munschauer, F.

AU - Kinkel, R. P.

AU - Bolibrush, D.

AU - Cohen, J.

AU - Freedman, M.

AU - Webb, U.

AU - Rabinowicz, H.

AU - Metz, L. M.

AU - Patry, D.

AU - Yeung, M.

AU - Peters, S.

AU - Hashimoto, S.

AU - Morrison, W.

AU - Oger, J.

AU - Panitch, H.

AU - Costello, K.

AU - Bever, C.

AU - Stuart, W.

AU - Court, D.

AU - Stuart, D.

AU - Tornatore, C.

AU - Bartlett, D.

AU - Richert, J.

AU - Duquette, P.

AU - Dubois, R.

AU - Bernier, G.

AU - Scott, T.

AU - Pappert, L.

AU - Brillman, J.

AU - Felton, W.

AU - Anderson, T.

AU - Astruc, J.

AU - Rose, J.

AU - Kline, J.

AU - Burns, J.

AU - Murray, T.

AU - Weldon, P.

AU - Bhan, V.

AU - Maxner, C. E.

AU - Wall, M.

AU - Vining, L.

AU - Grabowski, T.

AU - Apatoff, B.

AU - Orapello, C.

AU - Friedman, J.

AU - Galetta, S.

AU - Pfohl, D.

AU - Liu, G.

AU - Rice, G.

AU - Bental, T.

AU - Mandalfino, P.

AU - Eggenberger, E.

AU - Snider, D.

AU - Kaufman, D.

AU - Guarnaccia, J.

AU - Lesser, R.

AU - Goldstein, J.

AU - Reiss, M.

AU - Carter, E.

AU - Glista, G.

AU - Rolak, L.

AU - Scheller, L.

AU - Jacobson, D.

AU - Warner, J.

AU - Goodman, A.

AU - Petrie, M.

AU - Mattson, D.

AU - Karlin, K.

AU - Wallin, A.

AU - Stefoski, D.

AU - Brod, S.

AU - Cerretta, E.

AU - Wolinsky, J.

AU - Arnold, D.

AU - Arnoutelis, R.

AU - Durcan, L.

AU - Kupersmith, M.

AU - Cappolino, L.

AU - Herbert, J.

AU - Rosenberg, J.

AU - McHugh, D.

AU - Blumenfeld, A.

AU - Smith, C.

AU - Kuder, D.

AU - Hamilton, S.

AU - Thurston, S.

AU - McGee, J.

AU - O'Bannon, J.

AU - Kaufman, M.

AU - Butler, M.

AU - Putnam, S.

AU - Ramohan, K.

AU - Siffort, A.

PY - 2002/10/8

Y1 - 2002/10/8

N2 - Objective: To assess the ability of baseline MRI characteristics to predict the early development of clinically definite MS (CDMS) and combined CDMS/MRI outcomes in 190 patients with a positive MRI at the time of their first demyelinating event. Methods: Based on individual and sets of baseline MRI characteristics, the authors evaluated the percentage of patients meeting outcomes of CDMS and various combined CDMS/MRI outcomes by 18 months. They also optimized a cutpoint for dichotomizing each baseline MRI characteristic and evaluated these variables using logistic regression to determine which MRI characteristics best predicted CDMS by 18 months. Results: The presence of two or more gadolinium-enhancing lesions better predicted the development of CDMS and combined CDMS/MRI outcomes by 18 months than any other individual MRI characteristic or set of MRI characteristics. Among patients with two or more gadolinium-enhancing lesions, 52% developed CDMS compared with 24% of patients with fewer than two lesions. For those meeting the criteria of Barkhof et al., 32% of patients developed CDMS compared with 16% of those not meeting these criteria. Irrespective of individual or sets of criteria, however, the majority of patients developed either CDMS or demonstrated disease activity on brain MRI by 18 months. Conclusions: For patients with positive MRI at the time of their initial neurologic event, both gadolinium-enhancing lesions and the Barkhof criteria are predictors for development of CDMS over a short interval. However, these results, based on a combined CDMS/MRI outcome, suggest that the majority of these patients are already in the earliest stages of MS, regardless of whether any further MRI criteria are met.

AB - Objective: To assess the ability of baseline MRI characteristics to predict the early development of clinically definite MS (CDMS) and combined CDMS/MRI outcomes in 190 patients with a positive MRI at the time of their first demyelinating event. Methods: Based on individual and sets of baseline MRI characteristics, the authors evaluated the percentage of patients meeting outcomes of CDMS and various combined CDMS/MRI outcomes by 18 months. They also optimized a cutpoint for dichotomizing each baseline MRI characteristic and evaluated these variables using logistic regression to determine which MRI characteristics best predicted CDMS by 18 months. Results: The presence of two or more gadolinium-enhancing lesions better predicted the development of CDMS and combined CDMS/MRI outcomes by 18 months than any other individual MRI characteristic or set of MRI characteristics. Among patients with two or more gadolinium-enhancing lesions, 52% developed CDMS compared with 24% of patients with fewer than two lesions. For those meeting the criteria of Barkhof et al., 32% of patients developed CDMS compared with 16% of those not meeting these criteria. Irrespective of individual or sets of criteria, however, the majority of patients developed either CDMS or demonstrated disease activity on brain MRI by 18 months. Conclusions: For patients with positive MRI at the time of their initial neurologic event, both gadolinium-enhancing lesions and the Barkhof criteria are predictors for development of CDMS over a short interval. However, these results, based on a combined CDMS/MRI outcome, suggest that the majority of these patients are already in the earliest stages of MS, regardless of whether any further MRI criteria are met.

UR - http://www.scopus.com/inward/record.url?scp=0037044262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037044262&partnerID=8YFLogxK

U2 - 10.1212/wnl.59.7.998

DO - 10.1212/wnl.59.7.998

M3 - Article

C2 - 12370452

AN - SCOPUS:0037044262

SN - 0028-3878

VL - 59

SP - 998

EP - 1005

JO - Neurology

JF - Neurology

IS - 7

ER -

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Résumé

ASJC Scopus Subject Areas

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer